MARKET WIRE NEWS

Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript

Source: SeekingAlpha

2026-03-05 16:46:09 ET

Evogene Ltd. (EVGN) Q4 2025 Earnings Call March 5, 2026 9:00 AM EST

Company Participants

Ofer Haviv - CEO, President & Director
Yaron Eldad - Chief Financial Officer

Presentation

Operator ...

Welcome to Evogene's Fourth Quarter 2025 Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded, March 5, 2026.

Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events and Evogene Ltd., the company may from time to time, make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRA and other securities laws as amended.

Statements that are not statements of historical fact may be deemed to forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, plan, estimate, intend and potential or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimate market sizes and milestones, pipeline as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.

Therefore, actual future results, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups, Hamas and Hezbollah, Iran and other regional terrorist groups supported by Iran and any destabilizations in Israel, neighboring territories or the Middle East region and those described in greater detail in Evogene's annual report on Form 20-F and in other information Evogene files and furnished with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors.

Except as required by applicable security laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evogene or the company nor shall the information or any part of it or the fact of its distribution from the basis of or be relied on in connection with any action, contract, commitment or relating thereto or the securities of Evogene or the company.

The trademarks include herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our product or services. With us on the line will be Ofer Haviv, President and CEO of Evogene and Yaron Eldad, CFO of Evogene.

Now I will turn the call over to Ofer Haviv. Mr. Haviv, please go ahead.

Read the full article on Seeking Alpha

For further details see:

Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Evogene Ltd.

NASDAQ: EVGN

EVGN Trading

1.5% G/L:

$0.8331 Last:

21,873 Volume:

$0.8437 Open:

SMX Ad 300

EVGN Latest News

EVGN Stock Data

$6,644,881
6,267,035
N/A
7
N/A
Biotechnology & Life Sciences
Healthcare
IL
Rehovot

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App